Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,850 result(s) found for: Breast cancer. Displaying page 2 of 93.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-017788-40 Sponsor Protocol Number: KEO09069EST Start Date*: 2010-10-20
    Sponsor Name:CRLCC Alexis Vautrin
    Full Title: Etude de phase II randomisée multicentrique évaluant l'efficacité d’estramustine phosphate (Estracyt ®) chez des patientes présentant un cancer du sein métastatique HER2- / RH+ ayant déjà reçu un t...
    Medical condition: Metastases breast cancer in women already treated with aromatase inhibitors.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024067-41 Sponsor Protocol Number: COLTONE Start Date*: 2011-04-28
    Sponsor Name:F.A.R.O. FONDAZIONE PER LE ATTIVITA' DI RICERCA IN ONCOLOGIA
    Full Title: Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis...
    Medical condition: Elderly patients with diagnosis of early breast Cancer candidate to adjuvant chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004326-25 Sponsor Protocol Number: Shother 2007-004326-25 Start Date*: 2007-11-15
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: SHORT-HER: MULTICENTRIC RANDOMISED PHASE III TRIAL OF ADJUVANT CHEMOTHERAPY PLUS 3 VS 12 MONTHS OF TRASTUZUMAB IN BREAST CANCER PATIENTS WITH HER2 POSITIVE DISEASE
    Medical condition: carcinoma mammario con iperespressione di Her 2 o amplificazione dei geni codificanti per il recettore stesso.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023776-52 Sponsor Protocol Number: Lisette-1 Start Date*: 2011-01-19
    Sponsor Name:
    Full Title: Optimizing tamoxifen therapy through the induction of CYP3A4, CYP2C and CYP2D6 mediated metabolism
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019001-42 Sponsor Protocol Number: NEUGR-003 Start Date*: 2010-07-08
    Sponsor Name:Teva Pharmaceutical Works Private Limited Company
    Full Title: A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrasti...
    Medical condition: breast cancer patients receiving myelosupressive chemotherapy (doxorubicin/docetaxel)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-006262-28 Sponsor Protocol Number: IEO S438/508 Start Date*: 2009-06-03
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Allogeneic Haematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Refractory “Triple Negative”...
    Medical condition: Patients with Refractory “Triple Negative” Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006236-22 Sponsor Protocol Number: MET/TEST1106 Start Date*: 2007-01-31
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA
    Full Title: Use of Metformin to reduce serum level of Testosterone and improve the metabolic picture in women treated for breast cancer
    Medical condition: Menopausal women on treatment for BC, with higher risk of recurrence due to augmented level of T
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006187 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000520-14 Sponsor Protocol Number: IEO S291/106 Start Date*: 2006-10-26
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A PHASE II STUDY OF GW572016 LAPATINIBTM ON CELL PROLIFERATION IN HER-2/neu ErbB2 POSITIVE BREAST CANCER BEFORE SURGERY.
    Medical condition: Primary breast cancer T1-3 N0-1 M0 Histologically-confirmed HER 2 positive
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006187 PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-006025-27 Sponsor Protocol Number: IEOS380/607 Start Date*: 2008-11-10
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in adv...
    Medical condition: advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006430-10 Sponsor Protocol Number: CTKI258A2202 Start Date*: 2009-06-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, open label Phase II trial of TKI258 in FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.
    Medical condition: In female patients with FGFR1 amplified and non-amplified metastatic HER2 negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018795-24 Sponsor Protocol Number: APREC S-2010-01 Start Date*: 2010-06-01
    Sponsor Name:Alliance pour la recherche en cancérologie
    Full Title: Evaluation of the effect of pasireotide LAR administration in the lymphocele prevention after axillary node dissection for breast cancer
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005184-42 Sponsor Protocol Number: CLEE011A2412B Start Date*: 2022-04-15
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study
    Medical condition: HR+, HER2- advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000398-10 Sponsor Protocol Number: EFC16133 Start Date*: 2022-04-19
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A randomized, multicenter, double-blind, Phase 3 study of amcenestrant (SAR439859) versus tamoxifen for the treatment of patients with hormone receptor-positive, human epidermal growth factor 2-neg...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) EE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003576-19 Sponsor Protocol Number: I07015 Start Date*: 2007-10-18
    Sponsor Name:CHU de LIMOGES
    Full Title: Evaluation de l'efficacité et de la tolérance du Lanreotide LP 90 mg versus placebo dans la diminution de la lyphorrhée post curage axillaire dans les cancers du sein.
    Medical condition: cancer du sein
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002120-83 Sponsor Protocol Number: ICO-N-2016-02 Start Date*: 2016-10-05
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Full Title: Study evaluation of 2nd hormone line response by -[18F]fluoro-17β-œstradiol (FES) PET/CT in metastatic breast cancer patients
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007305 Carcinoma breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011113-25 Sponsor Protocol Number: SA2009 Start Date*: 2009-05-29
    Sponsor Name:Per Honore
    Full Title: Populationsbaseret farmakokinetisk og farmakodynamisk doseringsmodel af epirubicin, cyklofosfamid og docetaxel til brystkræft
    Medical condition: brystcancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-004234-41 Sponsor Protocol Number: 4102000 Start Date*: 2006-11-23
    Sponsor Name:Otto-von-Guericke Universität Magdeburg
    Full Title: Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®)
    Medical condition: metastasiertes Mammakarzinom
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017402-36 Sponsor Protocol Number: DEND/CM Start Date*: 2010-11-12
    Sponsor Name:Instituto Científico y Tecnológico de Navarra
    Full Title: Estudio prospectivo fase II de la vacunación con células dendríticas autólogas en pacientes con cáncer de mama triple negativo en estadios II-III
    Medical condition: Cáncer de mama triple negativo en estadíos II-III
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008698-69 Sponsor Protocol Number: CRAD001Y2301 Start Date*: 2009-07-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metasta...
    Medical condition: estrogen receptor positive locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) CZ (Completed) NL (Completed) FR (Completed) BE (Completed) GB (Completed) DE (Completed) SE (Completed) ES (Completed) HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002061-12 Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 Start Date*: 2007-08-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT...
    Medical condition: lymph node positive breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:20:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA